About this episode

The episode discusses a study comparing the safety of nafcillin and oxacillin in treating MSSA, highlighting significant differences in acute kidney injury rates.

Host Dr. Michael Rybak interviews Drs. Alejandro Perez and Autumn Brenner (UNC Medical Center) about their retrospective study, “Incidence of Acute Kidney Injury with the Use of Nafcillin versus Oxacillin,” comparing 171 nafcillin patients with 467 oxacillin patients. The study found a higher AKI rate with nafcillin (33.3%) versus oxacillin (19.5%), along with higher hypokalemia, suggesting these agents may not be clinically interchangeable from a safety standpoint. They discuss confounding concerns around observed mortality and length-of-stay differences, offer mechanistic explanations, and recommend close monitoring of creatinine and potassium—especially in high-risk patients.

More episodes of ACCP JOURNALS

• Ambient AI use in Ambulatory Pharmacy Clinical Practice - Ep 187 · July 14, 2026 · 36 min
• Pharmacotherapy and AI: Beyond the Fear, Towards Collaboration - Ep 185 · June 30, 2026 · 20 min

Explore listener stats, chart rankings, contacts and more on the ACCP JOURNALS podcast page.